The company has adopted a disciplined financial strategy, electing to drawdown only 50% of the committed funds initially. This approach aims to minimize financing costs and avoid shareholder dilution while providing sufficient runway to meet key clinical development targets. According to CEO Dr. Nina Webster, the support from international lenders signals growing confidence in the firm's specialized focus on addressing the rising global burden of kidney disease.

Under the terms of the agreement, Dimerix retains the flexibility to access additional capital, with the facility potentially reaching A$50 million by March 2027 if required. Repayment is structured to occur through future milestone payments from existing commercial partnerships, which currently hold the potential to generate up to A$237 million. The company remains focused on its lead asset, DMX-200, a chemokine receptor antagonist currently being tested for focal segmental glomerulosclerosis, a rare and life-threatening condition that currently lacks approved therapies.